Isosorbide mononitrate: Difference between revisions
No edit summary |
|||
| Line 39: | Line 39: | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ISOSORBIDE MONONITRATE TABLET [ZYDUS PHARMACEUTICALS (USA) INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=897a0327-25d4-4769-bd6a-0e674264017f | publisher = | date = | accessdate = 30 January 2014 }}</ref> | ISMN extended-release tablets are an oral extended-release formulation of ISMN, the major active metabolite of isosorbide dinitrate; most of the clinical activity of the dinitrate is attributable to the mononitrate. | ||
The principal pharmacological action of ISMN and all organic nitrates in general is relaxation of vascular smooth muscle, producing dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood, decreases [[venous return]] to the heart, thereby reducing [[left ventricular end-diastolic pressure]] and [[pulmonary capillary wedge pressure]] ([[preload]]). Arteriolar relaxation reduces systemic vascular resistance, and systolic arterial pressure and [[mean arterial pressure]] ([[afterload]]). Dilatation of the coronary arteries also occurs. The relative importance of preload reduction, [[afterload]] reduction, and coronary dilatation remains undefined.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = ISOSORBIDE MONONITRATE TABLET [ZYDUS PHARMACEUTICALS (USA) INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=897a0327-25d4-4769-bd6a-0e674264017f | publisher = | date = | accessdate = 30 January 2014 }}</ref> | |||
==References== | ==References== | ||
Revision as of 01:10, 31 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]
For patient information, click here.
Overview
Isosorbide mononitrate is a drug used principally in the treatment of angina pectoris and acts by dilating the blood vessels so as to reduce the blood pressure. It is sold in the USA by Kremers Urban under the trade name Monoket, also sold in the USA under the name Imdur, and marketed in the UK under the trade names: Monosorb, Chemydur. In India, this drug is available under the brand names of Ismo, Isonorm, Monotrate, Solotrate, and Monit.
Category
Vasodilator
US Brand Names
ISOSORBIDE MONONITRATE tablet® [Zydus Pharmaceuticals (USA) Inc.]
FDA Package Insert
| Indications and Usage | Dosage and Administration | Dosage Forms and Strengths | Contraindications | Warnings and Precautions | Adverse Reactions | Drug Interactions | Use in Specific Populations | Overdosage | Description | Clinical Pharmacology | Nonclinical Toxicology | Clinical Studies | How Supplied/Storage and Handling | Patient Counseling Information | Labels and Packages
Mechanism of Action
ISMN extended-release tablets are an oral extended-release formulation of ISMN, the major active metabolite of isosorbide dinitrate; most of the clinical activity of the dinitrate is attributable to the mononitrate.
The principal pharmacological action of ISMN and all organic nitrates in general is relaxation of vascular smooth muscle, producing dilatation of peripheral arteries and veins, especially the latter. Dilatation of the veins promotes peripheral pooling of blood, decreases venous return to the heart, thereby reducing left ventricular end-diastolic pressure and pulmonary capillary wedge pressure (preload). Arteriolar relaxation reduces systemic vascular resistance, and systolic arterial pressure and mean arterial pressure (afterload). Dilatation of the coronary arteries also occurs. The relative importance of preload reduction, afterload reduction, and coronary dilatation remains undefined.[1]
References
- ↑ "ISOSORBIDE MONONITRATE TABLET [ZYDUS PHARMACEUTICALS (USA) INC.]". Retrieved 30 January 2014.